Literature DB >> 17635123

Matrix metalloproteinases: useful and deleterious.

E Ganea1, M Trifan, A C Laslo, G Putina, C Cristescu.   

Abstract

MMPs (matrix metalloproteinases) are zinc-dependent endopeptidases that degrade both matrix and non-matrix proteins. They play an important role in morphogenesis, and in a wide range of processes including tissue repair and remodelling. Their abnormal expression contributes to pathological processes including arthritis, cancer, and cardiac and central nervous system diseases, which explains the large interest in finding specific MMP inhibitors for therapeutic use. In this review we describe the structural features of MMPs, with special emphasis on their interaction with specific inhibitors. The effect of new, hydroxamatebased inhibitors on MMP isolated from bovine brain is evaluated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635123     DOI: 10.1042/BST0350689

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  12 in total

1.  Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases.

Authors:  K A Paschos; D Canovas; N C Bird
Journal:  Hippokratia       Date:  2009-01       Impact factor: 0.471

2.  Matrix metalloproteinase 9 expression: new regulatory elements.

Authors:  Irina Surgucheva; Kumaravel Chidambaram; David A Willoughby; Andrei Surguchov
Journal:  J Ocul Biol Dis Infor       Date:  2010-08-05

3.  Spinal matrix metalloproteinase 3 mediates inflammatory hyperalgesia via a tumor necrosis factor-dependent mechanism.

Authors:  C A Christianson; B L Fitzsimmons; J-H Shim; A Agrawal; S M Cohen; X-Y Hua; T L Yaksh
Journal:  Neuroscience       Date:  2011-10-20       Impact factor: 3.590

4.  Effect of elastin-derived peptides on the production of tissue inhibitor of metalloproteinase-1, -2, and -3 and the ratios in various endothelial cell lines.

Authors:  Krzysztof Siemianowicz; Wirginia Likus; Tomasz Francuz; Wojciech Garczorz
Journal:  Exp Ther Med       Date:  2015-04-17       Impact factor: 2.447

5.  Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis.

Authors:  Pallavi Garg; Matam Vijay-Kumar; Lixin Wang; Andrew T Gewirtz; Didier Merlin; Shanthi V Sitaraman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-02       Impact factor: 4.052

6.  Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease.

Authors:  Ryan S Friese; Fangwen Rao; Srikrishna Khandrika; Brenda Thomas; Michael G Ziegler; Geert W Schmid-Schönbein; Daniel T O'Connor
Journal:  Clin Exp Hypertens       Date:  2009-10       Impact factor: 1.749

Review 7.  Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance.

Authors:  Konstantinos A Paschos; Ali W Majeed; Nigel C Bird
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

8.  Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.

Authors:  Rajesh Subramaniam; Manas K Haldar; Shakila Tobwala; Bratati Ganguly; D K Srivastava; Sanku Mallik
Journal:  Bioorg Med Chem Lett       Date:  2008-04-16       Impact factor: 2.823

9.  Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide-stimulated rat primary astrocytes.

Authors:  Soon Young Lee; Hee Jin Kim; Woo Jong Lee; So Hyun Joo; Se-Jin Jeon; Ji Woon Kim; Hee Sun Kim; Seol-Heui Han; Jongmin Lee; Seung Hwa Park; Jae Hoon Cheong; Won-Ki Kim; Kwang Ho Ko; Chan Young Shin
Journal:  Neurochem Res       Date:  2008-05-21       Impact factor: 3.996

10.  Alterations of specific biomarkers of metabolic pathways in vascular tree from patients with Type 2 diabetes.

Authors:  Bernal-Lopez M Rosa; Llorente-Cortes Vicenta; Gomez-Carrillo Victor; Lopez-Carmona Dolores; Calleja Fernando; Gomez-Huelgas Ricardo; Badimon Lina; Francisco J Tinahones
Journal:  Cardiovasc Diabetol       Date:  2012-07-24       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.